Figure 3.
Reponse and outcome according to CD30-associated parameters in TFHL and PTCL-NOS (exploratory analysis). ORR (A-B) and Kaplan-Meier estimate, with number of patients at risk and 95% CL of DOR (C-D), PFS (E-F), and OS (G-H) with relative impact of IHC CD30 expression on neoplastic cells (<10% vs ≥10%; left panels) and of enzyme-linked immunosorbent assay baseline sCD30 level (≤120 ng/mL vs >120 ng/mL; right panels). NA, not applicable; Pcorr, corrected P-value.

Reponse and outcome according to CD30-associated parameters in TFHL and PTCL-NOS (exploratory analysis). ORR (A-B) and Kaplan-Meier estimate, with number of patients at risk and 95% CL of DOR (C-D), PFS (E-F), and OS (G-H) with relative impact of IHC CD30 expression on neoplastic cells (<10% vs ≥10%; left panels) and of enzyme-linked immunosorbent assay baseline sCD30 level (≤120 ng/mL vs >120 ng/mL; right panels). NA, not applicable; Pcorr, corrected P-value.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal